Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 11/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638405 | 0.79 | PTGER4 (0.44) | NPC1PTGER4MAPT | |
| SCHEMBL5952186 | 0.76 | NPC1 (0.42) | NPC1PTGER4MAPTKLKB1F11 | |
| SCHEMBL3059528 | 0.74 | NPC1 (0.41) | NPC1PTGER4MAPTKLKB1F11 | |
| SCHEMBL30889616 | 0.74 | NPC1 (0.36) | NPC1MAPTKLKB1F11DGAT1 | |
| SCHEMBL1316068 | 0.73 | NPC1 (0.35) | NPC1MAPTKLKB1F11DGAT1 | |
| SCHEMBL20553221 | 0.70 | NPC1 (0.36) | NPC1MAPTF11DGAT1 | |
| SCHEMBL20551555 | 0.70 | NPC1 (0.36) | NPC1PTGER4MAPTDGAT1 | |
| SCHEMBL12381935 | 0.70 | NPC1 (0.37) | NPC1MAPTKLKB1F11DGAT1 | |
| SCHEMBL1314051 | 0.70 | NPC1 (0.35) | NPC1MAPTKLKB1F11DGAT1 | |
| SCHEMBL5374515 | 0.70 | NPC1 (0.37) | NPC1MAPTKLKB1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | NPC1 794/4885PTGER4 74/4885MAPT 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.